Publications

publications image

 

(2022)

Sharrock AV*, Mulligan TS*, Hall KR, Williams EM, White DT, Zhang L, Emmerich K, Matthews F, Nimmagadda S, Washington S, Le KD, Meir-Levi D, Cox OL, Saxena MT, Calof AL, Lopez-Burks ME, Lander AD, Ding D, Ji H, Ackerley DF*, Mumm JS*. (2022). NTR 2.0: a rationally engineered prodrug-converting enzyme with substantially enhanced efficacy for targeted cell ablation. Nature Methods. 19. 205-215
Stevenson LJ, Ackerley DF, Owen JG. (2022). Preparation of Soil Metagenome Libraries and Screening for Gene-Specific Amplicons. Methods in Molecular Biology. 2397. 3-17
Ashoorzadeh A, Mowday AM, Guise CP, Silva S, Bull MR, Abbattista MR, Copp JN, Williams EM, Ackerley DF, Patterson AV, Smaill JB. (2022). Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications. Pharmaceuticals. 15. 182
Hall CJ, Astin JW, Mumm JS, Ackerley DF. (2022). A New Transgenic Line for Rapid and Complete Neutrophil Ablation. Zebrafish. 19. 109-113
Abbattista MR, Ashoorzadeh A, Guise CP, Mowday AM, Mittra R, Silva S, Hicks KO, Bull MR, Jackson-Patel V, Lin X, Prosser GA, Lambie NK, Dachs GU, Ackerley DF, Smaill JB, Patterson AV. (2022). Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3. Pharmaceuticals. 14. 1231
Mowday AM, Dubois LJ, Kubiak AM, Chan-Hyams JVE, Guise CP, Ashoorzadeh A, Lambin P, Ackerley DF, Smaill JB, Minton NP, Theys J, Patterson AV. (2022). Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Cancer Gene Therapy. 29. 178-188

(2021)

Bracegirdle, J., Stevenson, L. J., Sharrock, A. V., Page, M. J., Vorster, J. A., Owen, J. G., Ackerley, D. F. & Keyzers, R. A. (2021). Hydrated Rubrolides from the New Zealand Tunicate Synoicum kuranui. Journal of natural products. 83(2). 544-547
Stevenson, L.J., Bracegirdle, J., Liu, L., Sharrock, A.V., Ackerley, D.F., Keyzers, R.A., & Owen, J.G. (2021). Metathramycin, a new bioactive aureolic acid discovered by heterologous expression of a metagenome derived biosynthetic pathway. RSC Chemical Biology. 2. 556-567
Zhang, L., Chen, C., Fu,J., Lilley, B., Berlinicke, C., Hansen, B., Ding, D., Wang, G., Wang, T., Shou, D., Ye, Y., Mulligan, T., Emmerich, K., Saxena, M., Hall, K., Sharrock, A., Brandon, C., Park, H., Kam, T., Dawson, V., Dawson, T., Shim, J., Hanes, J., Ji, H., Liu, J., Qian, J., Ackerley, D., Rohrer, B., Zack, D. & Mumm, J. (2021). Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. Elife. 10. e57245
Sharrock, A.V., McManaway, S.P., Rich, M.H., Mumm, J.S., Hermans, I.F., Tercel, M., Pruijn, F.B., Ackerley, D.F. (2021). Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System. Frontiers in Pharmacology. 12. 1420
Brown, A. S., Owen, J. G., Jung, J., Baker, E. N. & Ackerley, D. F. (2021). Inhibition of Indigoidine Synthesis as a High-Throughput Colourimetric Screen for Antibiotics Targeting the Essential Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT. Pharmaceutics. 13(7). 1066
Mowday, A.M., Dubois, L.J., Kubiak, A.M., Chan-Hyams, J.V.E., Guise, C.P., Ashoorzadeh, A., Lambin, P., Ackerley, D.F., Smaill, J.B., Minton, N.P., Theys. J. & Patterson A.V. (2021). Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Cancer Gene Therapy. 29. 178-188
Rich, M. H., Sharrock, A. V., Ashoorzadeh, A., Patterson, A. V., Smaill, J. B. & Ackerley, D. F. (2021). Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug. Biotechnology Letters. 43(1). 203-211

(2020)

Brown, A. S., Sissons, J. A., Owen, J. G., & Ackerley, D. F. (2020). Directed Evolution of the Nonribosomal Peptide Synthetase BpsA to Enable Recognition by the Human Phosphopantetheinyl Transferase for Counter-Screening Antibiotic Candidates. ACS Infectious Diseases. 6(11). 2879-2886.
Copp, J. N., Pletzer, D., Brown, A. S., Van der Heijden, J., Miton, C. M., Edgar, R. J., Rich, M. H., Little, R. F., Williams, E. M., Hancock, R., Tokuriki, N., & Ackerley, D. F. (2020). Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections. mBio. 11(5). e02068-20